Stocks Health care EOLS
NASDAQ · Health careEvolus, Inc. (EOLS)
Evolus, Inc. brought in $316.5M of revenue over the twelve months to June 30, 2026, up 13.9% from a year earlier. It posted a net loss of $34.3M. In fiscal 2025 capital spending exceeded operating cash flow by $45.7M. At June 30, 2026 it held $45.2M in cash against $156.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Evolus, Inc. does
Evolus, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EOLS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $297.2M | -$51.6M | -$0.80 | -$45.7M |
| 2024 | $266.3M | -$50.4M | -$0.81 | -$19.5M |
| 2023 | $202.1M | -$61.7M | -$1.08 | -$34.5M |
| 2022 | $148.6M | -$74.4M | -$1.33 | -$86.5M |
| 2021 | $99.7M | -$46.8M | -$0.94 | -$33.8M |
| 2020 | $56.5M | -$163M | -$4.83 | -$58.7M |
Latest SEC filings
What Evolus, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 31, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- August 4, 2026
- July 8, 2026
- June 12, 2026
- June 5, 2026
- May 4, 2026Quarterly report 10-Q · period to March 31, 2026
- May 4, 2026
- April 29, 2026Additional proxy material DEFA14A
Questions about EOLS
What does Evolus, Inc. do?
Evolus, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EOLS.
Is Evolus, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $34.3M on revenue of $316.5M.
How much revenue does Evolus, Inc. make?
Over the twelve months to June 30, 2026 Evolus, Inc. reported revenue of $316.5M. That is 13.9% more than a year earlier.
When did Evolus, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 4, 2026.
Similar companies
Follow EOLS
Get an email when Evolus, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow EOLS: get an email when it filesWhere the numbers come from
Financial figures are the values Evolus, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.